Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sarepta Therapeutics's change in inventory for the quarter that ended in Jun. 2026 was MXN696 Mil. It means Sarepta Therapeutics's inventory
declined by MXN696 Mil
from Mar. 2026 to Jun. 2026 .
Sarepta Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was MXN-5,421 Mil. It means Sarepta Therapeutics's inventory
increased by MXN5,421 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Sarepta Therapeutics's Days Inventory for the quarter that ended in Jun. 2026 was 592.17.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sarepta Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.15.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sarepta Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 2.42.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sarepta Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics Change In Inventory Related Terms
Sarepta Therapeutics Change In Inventory Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,752 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of MXN-1,752 Mil mean?
Sarepta Therapeutics (MEX:SRPT) has a Change In Inventory of MXN-1,752 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Change In Inventory too high?
Sarepta Therapeutics' current Change In Inventory is MXN-1,752 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Change In Inventory compare to MPLT and ZYME?
Sarepta Therapeutics' Change In Inventory of MXN-1,752 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Change In Inventory is MXN-1,752 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN1,769.80, compared to a current price of MXN280.23 — trading 84.2% below its estimated fair value. The current Change In Inventory is MXN-1,752 Mil. Sarepta Therapeutics' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Change In Inventory is MXN-1,752 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of MXN280.23 is trading 84.2% below its estimated GF Value™ of MXN1,769.80.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for MEX:SRPT:
Change In Inventory: MXN-1,752 Mil
GF Value™: MXN1,769.80 vs. price of MXN280.23 (84.2% below fair value)
No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score
Get the complete analysis for MEX:SRPT
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SRPT has been successfully added to your 
